A Midtown-based medical device startup is carving a niche in the growing field of treatments to address chronic lung disease.

The study, involving five patients, demonstrated the procedural efficiency and feasibility of AerWave's technology.

AerWave’s ultrasound platform delivers precise treatment in one simple targeted ablation procedure while avoiding sensitive areas like peri esophageal nerves.

- Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary ...

AerWave Medical has concluded the feasibility study of its ultrasound lung denervation therapy, designed to treat chronic obstructive pulmonary disease (COPD) and asthma. The first-in-human study ...

- Company has also raised $12 million in funding led by Lucius Partners NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- AerWave Medical , a leader in ultrasound-based interventional pulmonary solutions, today announced the successful completion of its first-in-human (FIH ...